US Stock Market Move | Cardiovascular pharmaceutical company Braveheart Bio (BRVE.US) debuts on the U.S. stock market, with its stock price rising over 75% after opening.

00:00 07/08/2026

As of the press release, the stock has risen over 75%, trading at $31.405.

On Thursday, cardiovascular pharmaceutical company Braveheart Bio (BRVE.US) made its debut on the U.S. stock market. As of the time of writing, the stock has surged over 75%, trading at $31.405. The IPO price was $18. Founded in 2024, Braveheart Bio is a late-stage biopharmaceutical company focused on developing innovative therapies for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. The company's lead candidate BHB-1893 (also known as HRS-1893) is an oral small molecule myosin inhibitor that normalizes myocardial contractility by specifically inhibiting myocardial myosin ATPase activity, reducing left ventricular hypertrophy and improving diastolic compliance. The drug was granted global (excluding Greater China) exclusive licensing rights from Jiangsu Hengrui Pharmaceuticals in September 2025.

IMF Vice President: Japan's economy is experiencing a long-term structural recovery, supporting the Bank of Japan in continuing to advance the normalization of monetary policy.

US Stock Market Move | AppLovin (APP.US) plummeted over 20% as Q3 guidance fell short of expectations.

The initial release of approximately $100 billion worth of stocks did not trigger a wave of sell-offs. SpaceX (SPCX.US) shares experienced slight fluctuations, while market sentiment remains relatively bearish.

IMF Vice President: Japan's economy is experiencing a long-term structural recovery, supporting the Bank of Japan in continuing to advance the normalization of monetary policy.

US Stock Market Move | AppLovin (APP.US) plummeted over 20% as Q3 guidance fell short of expectations.